PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to compare the efficacy of voice therapy combined with standard anti-reflux therapy in reducing symptoms and signs of laryngopharyngeal reflux (LPR).
UNASSIGNED: A randomised clinical trial was conducted. Fifty-two patients with LPR diagnosed by 24 h multichannel intraluminal impedance-pH monitoring were randomly allocated in two groups: medical treatment (MT) and medical plus voice therapy (VT). Clinical symptoms and laryngeal signs were assessed at baseline and after 3 months of treatment with the Reflux Symptom Index (RSI), Reflux Finding Score (RFS), Voice Handicap Index (VHI) and GRBAS scales.
UNASSIGNED: Groups had similar scores at baseline. At 3-month follow-up, a significant decrease in RSI and RFS total scores were found in both groups although it appeared to be more robust in the VT group. G and R scores of the GRBAS scale significantly improved after treatment in both groups, with better results in the VT group. The VHI total score at 3 months improved more in the VT group (VHI delta 9.54) than in the MT group (VHI delta 5.38) (p < 0.001).
UNASSIGNED: The addition of voice therapy to medications and diet appears to be more effective in improving treatment outcomes in subjects with LPR. Voice therapy warrants consideration in addition to medication and diet when treating patients with LPR.
UNASSIGNED: A randomised clinical trial was conducted. Fifty-two patients with LPR diagnosed by 24 h multichannel intraluminal impedance-pH monitoring were randomly allocated in two groups: medical treatment (MT) and medical plus voice therapy (VT). Clinical symptoms and laryngeal signs were assessed at baseline and after 3 months of treatment with the Reflux Symptom Index (RSI), Reflux Finding Score (RFS), Voice Handicap Index (VHI) and GRBAS scales.
UNASSIGNED: Groups had similar scores at baseline. At 3-month follow-up, a significant decrease in RSI and RFS total scores were found in both groups although it appeared to be more robust in the VT group. G and R scores of the GRBAS scale significantly improved after treatment in both groups, with better results in the VT group. The VHI total score at 3 months improved more in the VT group (VHI delta 9.54) than in the MT group (VHI delta 5.38) (p < 0.001).
UNASSIGNED: The addition of voice therapy to medications and diet appears to be more effective in improving treatment outcomes in subjects with LPR. Voice therapy warrants consideration in addition to medication and diet when treating patients with LPR.
摘要：
■这项研究的目的是比较嗓音疗法与标准抗反流疗法在减轻咽喉反流（LPR）症状和体征方面的疗效。
■进行了一项随机临床试验。通过24h多通道腔内阻抗-pH监测诊断为LPR的52例患者随机分为两组：药物治疗（MT）和药物加语音治疗（VT）。在基线和治疗3个月后用反流症状指数（RSI）评估临床症状和喉部体征，反流发现分数（RFS），语音障碍指数(VHI)和GRBAS量表。
■组在基线时得分相似。在3个月的随访中，两组的RSI和RFS总分均显著下降,尽管在VT组中似乎更为稳健.两组治疗后GRBAS量表G、R评分均有明显改善,VT组的结果更好。VT组（VHIdelta9.54）比MT组（VHIdelta5.38）在3个月时的VHI总分改善更多（p<0.001）。
在药物和饮食中加入语音治疗似乎更有效地改善了LPR患者的治疗结果。在治疗LPR患者时，除了药物和饮食外，语音疗法还需要考虑。
■进行了一项随机临床试验。通过24h多通道腔内阻抗-pH监测诊断为LPR的52例患者随机分为两组：药物治疗（MT）和药物加语音治疗（VT）。在基线和治疗3个月后用反流症状指数（RSI）评估临床症状和喉部体征，反流发现分数（RFS），语音障碍指数(VHI)和GRBAS量表。
■组在基线时得分相似。在3个月的随访中，两组的RSI和RFS总分均显著下降,尽管在VT组中似乎更为稳健.两组治疗后GRBAS量表G、R评分均有明显改善,VT组的结果更好。VT组（VHIdelta9.54）比MT组（VHIdelta5.38）在3个月时的VHI总分改善更多（p<0.001）。
在药物和饮食中加入语音治疗似乎更有效地改善了LPR患者的治疗结果。在治疗LPR患者时，除了药物和饮食外，语音疗法还需要考虑。
